|  | 
   |  | 
   |  | 
   |  | 
   |  | 
   |  | 
   | 
         
            
               | 30.10.25 - 12:01 | Haleon Q3 Revenue Inches Up (AFX) |  
               |  | 
                     LONDON (dpa-AFX) - Haleon plc (HLN.L), a British pharmaceutical company, Thursday reported that its revenue rose slightly for the third quarter compared to the same period of last year.Quarterly r......
                   |  | 
   |  | 
   | 
         
            
               | 29.09.25 - 20:12 | Emma Walmsley steadied GSK – but doubts linger over growth targets (The Guardian) |  
               |  | 
                     The outgoing chief executive reshaped the drugmaker, yet scepticism persists over promised revenuesGSK's Emma Walmsley to step down as chief executive after eight years“I am a change agent,” declared Emma Walmsley soon after she became chief executive of GlaxoSmithKline in 2017 and, sure enough, the UK's second largest pharmaceutical company does indeed look different from eight years ago.The consumer health division has gone – it was demerged as Haleon in 2023, which ended the debate about whether GSK required a bigger break-up. And annual budgets for research and development in pharmaceuticals and vaccines have been doubled in her time, which got to the core of the drugmaker's ills. Continue reading......
                   |  | 
   | 
         
            
               | 25.09.25 - 14:33 | Revision Skincare® Appoints Lisa Paley as CEO to Propel the Company′s Next Phase of Growth (Business Wire) |  
               |  | 
                     Paley Brings Over 25 Years of Leadership Experience Across Consumer Healthcare and Wellness at Haleon, GSK, Pfizer and Johnson & JohnsonIRVING, Texas--(BUSINESS WIRE)--Revision Skincare®, a leader in advanced skincare solutions, today announced the appointment of Lisa Paley as CEO. A highly experienced, transformational leader, Paley has nearly three decades of executive experience spanning several of the world's leading consumer healthcare companies, including Haleon, GSK, Pfizer and Johnson & Johnson.
“Lisa's extensive experience building science-backed brands across the consumer health, wellness and beauty spectrum makes her the ideal leader to accelerate our business in the US and key global markets,” said Matt Farron, Partner, Co-Head of Consumer Group at Gryphon Investors. “She has a stellar reputation as a visionary leader who can deliver sustained growth, scale innovation across geographies and build high-performance cultures with an engaging, people-driven leadership style. We're thrill...
                   |  | 
   |  | 
   |  | 
   |  | 
   |  | 
   | 
         
            
               | 11.09.25 - 07:48 | £10,000 invested in Haleon shares 1 year ago is now worth… (Fool) |  
               |  | 
                     Haleon shares are among the most traded on the FTSE 100 but arguably don't get the attention they deserve. Dr James Fox takes a closer look.
The post £10,000 invested in Haleon shares 1 year ago is now worth… appeared first on The Motley Fool UK....
                   |  | 
   |  | 
   |  | 
   | 
         
            
               | 12.08.25 - 23:45 | XFRA: DIVIDEND/INTEREST INFORMATION - 14.08.2025 - GB00BMX86B70 (XETRA) |  
               |  | 
                     Das Instrument H6D0 GB00BMX86B70 HALEON PLC       LS 0,01 EQUITY wird cum Dividende/Zinsen gehandelt am 13.08.2025 und ex Dividende/Zinsen am 14.08.2025
The instrument H6D0 GB00BMX86B70 HALEON PLC       LS 0,01 EQUITY has its pre-dividend/interest day on 13.08.2025 and its ex-dividend/interest day on 14.08.2025...
                   |  | 
   |  | 
   |  | 
   |  |